Analysts at HC Wainwright began coverage on shares of Nektar Therapeutics (NASDAQ:NKTR) in a report issued on Monday, August 7th, MarketBeat Ratings reports. The firm set a “buy” rating and a $31.00 price target on the biopharmaceutical company’s stock. HC Wainwright’s price objective points to a potential upside of 71.84% from the stock’s previous close.

A number of other research analysts have also commented on the stock. Jefferies Group LLC lowered their price objective on shares of Nektar Therapeutics from $25.00 to $23.00 and set a “buy” rating on the stock in a research note on Wednesday, May 10th. Aegis restated a “buy” rating and issued a $27.00 price target on shares of Nektar Therapeutics in a research report on Wednesday, May 10th. Roth Capital set a $31.00 price target on shares of Nektar Therapeutics and gave the stock a “buy” rating in a research report on Thursday, May 11th. William Blair restated an “outperform” rating on shares of Nektar Therapeutics in a research report on Tuesday, July 18th. Finally, BidaskClub upgraded shares of Nektar Therapeutics from a “hold” rating to a “buy” rating in a research report on Tuesday, June 27th. Four equities research analysts have rated the stock with a hold rating and nine have given a buy rating to the company’s stock. The stock presently has an average rating of “Buy” and a consensus target price of $26.10.

Shares of Nektar Therapeutics (NKTR) traded down 2.06% during midday trading on Monday, hitting $18.04. The company had a trading volume of 1,075,725 shares. The company has a 50-day moving average of $20.49 and a 200 day moving average of $18.57. Nektar Therapeutics has a 12 month low of $11.41 and a 12 month high of $24.88. The firm’s market capitalization is $2.82 billion.

Nektar Therapeutics (NASDAQ:NKTR) last posted its quarterly earnings data on Tuesday, August 8th. The biopharmaceutical company reported ($0.39) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.35) by $0.04. Nektar Therapeutics had a negative net margin of 157.14% and a negative return on equity of 1,223.34%. The company had revenue of $34.60 million for the quarter, compared to analyst estimates of $33.64 million. During the same quarter in the prior year, the business earned ($0.36) EPS. Nektar Therapeutics’s revenue was up 5.5% compared to the same quarter last year. On average, analysts expect that Nektar Therapeutics will post ($0.94) EPS for the current fiscal year.

ILLEGAL ACTIVITY NOTICE: “Nektar Therapeutics (NASDAQ:NKTR) Now Covered by HC Wainwright” was originally published by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are accessing this piece of content on another website, it was copied illegally and reposted in violation of international copyright & trademark laws. The original version of this piece of content can be accessed at https://www.thecerbatgem.com/2017/08/19/nektar-therapeutics-nasdaqnktr-receives-new-coverage-from-analysts-at-hc-wainwright-updated.html.

In other Nektar Therapeutics news, SVP Ivan P. Gergel sold 8,389 shares of the business’s stock in a transaction dated Tuesday, July 11th. The shares were sold at an average price of $21.04, for a total value of $176,504.56. Following the transaction, the senior vice president now directly owns 51,961 shares in the company, valued at $1,093,259.44. The transaction was disclosed in a document filed with the SEC, which is available through this link. Also, CEO Howard W. Robin sold 91,714 shares of the business’s stock in a transaction dated Wednesday, August 16th. The shares were sold at an average price of $19.26, for a total transaction of $1,766,411.64. Following the completion of the transaction, the chief executive officer now owns 152,504 shares in the company, valued at $2,937,227.04. The disclosure for this sale can be found here. In the last ninety days, insiders sold 237,629 shares of company stock valued at $4,820,217. 6.10% of the stock is owned by company insiders.

Institutional investors have recently made changes to their positions in the company. Flinton Capital Management LLC raised its position in shares of Nektar Therapeutics by 11.1% in the first quarter. Flinton Capital Management LLC now owns 4,480 shares of the biopharmaceutical company’s stock worth $105,000 after buying an additional 448 shares during the last quarter. Zurcher Kantonalbank Zurich Cantonalbank raised its position in shares of Nektar Therapeutics by 14.1% in the second quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 5,603 shares of the biopharmaceutical company’s stock worth $110,000 after buying an additional 692 shares during the last quarter. Meadow Creek Investment Management LLC raised its position in shares of Nektar Therapeutics by 11.1% in the first quarter. Meadow Creek Investment Management LLC now owns 6,160 shares of the biopharmaceutical company’s stock worth $145,000 after buying an additional 616 shares during the last quarter. LS Investment Advisors LLC raised its position in shares of Nektar Therapeutics by 8.8% in the second quarter. LS Investment Advisors LLC now owns 6,594 shares of the biopharmaceutical company’s stock worth $129,000 after buying an additional 535 shares during the last quarter. Finally, Glen Harbor Capital Management LLC raised its position in shares of Nektar Therapeutics by 11.1% in the first quarter. Glen Harbor Capital Management LLC now owns 7,840 shares of the biopharmaceutical company’s stock worth $184,000 after buying an additional 784 shares during the last quarter. Institutional investors own 93.02% of the company’s stock.

Nektar Therapeutics Company Profile

Nektar Therapeutics is a biopharmaceutical company that discovers and develops medicines in areas of high unmet medical need. The Company’s research and development pipeline of new investigational drugs includes treatments for cancer, auto-immune disease and chronic pain. It leverages its chemistry platform to discover and design new drug candidates.

Analyst Recommendations for Nektar Therapeutics (NASDAQ:NKTR)

Receive News & Stock Ratings for Nektar Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nektar Therapeutics and related stocks with our FREE daily email newsletter.